TGF-β participates choroid neovascularization through Smad2/3-VEGF/TNF-α signaling in mice with Laser-induced wet age-related macular degeneration

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Wang, Xiaolei ^a,b   Ma, Wei ^b,c   Han, Song ^b   Meng, Zhaoyang ^a   Zhao, Lu ^a   Yin, Yi ^a   Wang, Yanling ^a   Li, Junfa ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b BEIJING INSTITUTE FOR BRAIN DISORDERS   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

SMAD2 PROTEIN; SMAD2 PROTEIN, MOUSE; SMAD3 PROTEIN; SMAD3 PROTEIN, MOUSE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

ANIMAL; COMPLICATION; CYTOCHEMISTRY; DISEASE MODEL; FLUORESCENCE ANGIOGRAPHY; FLUORESCENCE MICROSCOPY; LASER; MACULAR DEGENERATION; METABOLISM; MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; SUBRETINAL NEOVASCULARIZATION; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CHOROIDAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; FLUORESCEIN ANGIOGRAPHY; HISTOCYTOCHEMISTRY; LASERS; MACULAR DEGENERATION; MICE; MICROSCOPY, FLUORESCENCE; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85028467203     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-10124-4     Document Type: Article

References (41)

1. Ryskulova, A. et al. Self-reported age-related eye diseases and visual impairment in the United States: results of the 2002 national health interview survey. American journal of public health 98, 454-461, doi:10.2105/AJPH.2006.098202 (2008).
2. Tomany, S. C. et al. Risk factors for incident age-related macular degeneration: pooled findings from 3 continents. Ophthalmology 111, 1280-1287, doi:10.1016/j.ophtha.2003.11.010 (2004).
3. Birke, K., Lipo, E., Birke, M. T. & Kumar-Singh, R. Topical application of PPADS inhibits complement activation and choroidal neovascularization in a model of age-related macular degeneration. PloS one 8, e76766, doi:10.1371/journal.pone.0076766 (2013).
4. Freund, K. B., Mrejen, S. & Gallego-Pinazo, R. An update on the pharmacotherapy of neovascular age-related macular degeneration. Expert opinion on pharmacotherapy 14, 1017-1028, doi:10.1517/14656566.2013.787410 (2013).
5. Rattner, A. & Nathans, J. Macular degeneration: recent advances and therapeutic opportunities. Nature reviews. Neuroscience 7, 860-872, doi:10.1038/nrn2007 (2006).
6. Semkova, I. et al. Anti-angiogenic effect of the basement membrane protein nidogen-1 in a mouse model of choroidal neovascularization. Experimental eye research 118, 80-88, doi:10.1016/j.exer.2013.11.006 (2014).
7. Tsutsumi, C. et al. The critical role of ocular-infiltrating macrophages in the development of choroidal neovascularization. Journal of leukocyte biology 74, 25-32 (2003).
8. Krzystolik, M. G. et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Archives of ophthalmology 120, 338-346 (2002).
9. Sakurai, E., Anand, A., Ambati, B. K., van Rooijen, N. & Ambati, J. Macrophage depletion inhibits experimental choroidal neovascularization. Investigative ophthalmology & visual science 44, 3578-3585 (2003).
10. Bhutto, I. A. et al. Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration. Experimental eye research 82, 99-110, doi:10.1016/j.exer.2005.05.007 (2006).
11. Lu, M. & Adamis, A. P. Molecular biology of choroidal neovascularization. Ophthalmology clinics of North America 19, 323-334, doi:10.1016/j.ohc.2006.05.001 (2006).
12. Lyzogubov, V. et al. Complement regulatory protein CD46 protects against choroidal neovascularization in mice. The American journal of pathology 184, 2537-2548, doi:10.1016/j.ajpath.2014.06.001 (2014).
13. Brand, C. S. Management of retinal vascular diseases: a patient-centric approach. Eye 26(Suppl 2), S1-16, doi:10.1038/eye.2012.32 (2012).
14. Keane, P. A. & Sadda, S. R. Development of Anti-VEGF Therapies for Intraocular Use: A Guide for Clinicians. Journal of ophthalmology 2012, 483034, doi:10.1155/2012/483034 (2012).
15. Shima, C. et al. Complications in patients after intravitreal injection of bevacizumab. Acta ophthalmologica 86, 372-376, doi:10.1111/j.1600-0420.2007.01067.x (2008).
16. Wu, L. et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 246, 81-87, doi:10.1007/s00417-007-0660-z (2008).
17. Zhang, P., Su, Y. & Liu, F. The relationship between intervention in the CD40 signal pathway and choroidal neovascularization. OncoTargets and therapy 7, 263-267, doi:10.2147/OTT.S56909 (2014).
18. Nagineni, C. N. et al. Transforming growth factor-beta induces expression of vascular endothelial growth factor in human retinal pigment epithelial cells: involvement of mitogen-activated protein kinases. Journal of cellular physiology 197, 453-462, doi:10.1002/jcp.10378 (2003).
19. Seuntjens, E. et al. Transforming Growth Factor type beta and Smad family signaling in stem cell function. Cytokine & growth factor reviews 20, 449-458, doi:10.1016/j.cytogfr.2009.10.005 (2009).
20. Shi, Y. & Massague, J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113, 685-700 (2003).
21. Simo, R., Carrasco, E., Garcia-Ramirez, M. & Hernandez, C. Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Current diabetes reviews 2, 71-98 (2006).
22. Loukovaara, S. et al. Ang-2 upregulation correlates with increased levels of MMP-9, VEGF, EPO and TGFbeta1 in diabetic eyes undergoing vitrectomy. Acta ophthalmologica 91, 531-539, doi:10.1111/j.1755-3768.2012.02473.x (2013).
23. Ferrari, G., Cook, B. D., Terushkin, V., Pintucci, G. & Mignatti, P. Transforming growth factor-beta 1 (TGF-beta1) induces angiogenesis through vascular endothelial growth factor (VEGF)-mediated apoptosis. Journal of cellular physiology 219, 449-458, doi:10.1002/jcp.21706 (2009).
24. van Royen, N. et al. Exogenous application of transforming growth factor beta 1 stimulates arteriogenesis in the peripheral circulation. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 16, 432-434, doi:10.1096/fj.01-0563fje (2002).
25. Shi, X. et al. TGF-beta/Smad3 inhibit vascular smooth muscle cell apoptosis through an autocrine signaling mechanism involving VEGF-A. Cell death & disease 5, e1317, doi:10.1038/cddis.2014.282 (2014).
26. Nunes, I. et al. Structure and activation of the large latent transforming growth factor-Beta complex. Journal of the American Optometric Association 69, 643-648 (1998).
27. Bueno, L. et al. Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice. European journal of cancer 44, 142-150, doi:10.1016/j.ejca.2007.10.008 (2008).
28. Nassar, K. et al. The novel use of decorin in prevention of the development of proliferative vitreoretinopathy (PVR). Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 249, 1649-1660, doi:10.1007/s00417-011-1730-9 (2011).
29. Lu, H. et al. IKK2 inhibition attenuates laser-induced choroidal neovascularization. PloS one 9, e87530, doi:10.1371/journal. pone.0087530 (2014).
30. Parodi, M. B., Iacono, P., Papayannis, A., Sheth, S. & Bandello, F. Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia. Archives of ophthalmology 128, 437-442, doi:10.1001/archophthalmol.2009.408 (2010).
31. Ruiz-Moreno, J. M., Montero, J. A. & Zarbin, M. A. Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative age-related macular degeneration: 2-year outcome. Retina 27, 458-461, doi:10.1097/IAE.0b013e318030c77c (2007).
32. Bian, Z. M., Elner, S. G. & Elner, V. M. Regulation of VEGF mRNA expression and protein secretion by TGF-beta2 in human retinal pigment epithelial cells. Experimental eye research 84, 812-822, doi:10.1016/j.exer.2006.12.016 (2007).
33. Holderfield, M. T. & Hughes, C. C. Crosstalk between vascular endothelial growth factor, notch, and transforming growth factorbeta in vascular morphogenesis. Circulation research 102, 637-652, doi:10.1161/CIRCRESAHA.107.167171 (2008).
34. Nagineni, C. N. et al. Resveratrol Suppresses Expression of VEGF by Human Retinal Pigment Epithelial Cells: Potential Nutraceutical for Age-related Macular Degeneration. Aging and disease 5, 88-100, doi:10.14366/AD.2014.050088 (2014).
35. Zarranz-Ventura, J. et al. Transforming growth factor-beta inhibition reduces progression of early choroidal neovascularization lesions in rats: P17 and P144 peptides. PloS one 8, e65434, doi:10.1371/journal.pone.0065434 (2013).
36. Yingchuan, F., Chuntao, L., Hui, C. & Jianbin, H. Increased expression of TGF-beta1 and Smad 4 on oxygen-induced retinopathy in neonatal mice. Advances in experimental medicine and biology 664, 71-77, doi:10.1007/978-1-4419-1399-9-9 (2010).
37. Xie, P. et al. Suppression of experimental choroidal neovascularization by curcumin in mice. PloS one 7, e53329, doi:10.1371/journal. pone.0053329 (2012).
38. Zhang, J. et al. The regulation of TGF-beta/SMAD signaling by protein deubiquitination. Protein & cell 5, 503-517, doi:10.1007/s13238-014-0058-8 (2014).
39. Drabsch, Y. & ten Dijke, P. TGF-beta signalling and its role in cancer progression and metastasis. Cancer metastasis reviews 31, 553-568, doi:10.1007/s10555-012-9375-7 (2012).
40. Massague, J., Blain, S. W. & Lo, R. S. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 103, 295-309 (2000).
41. Wang, X. et al. LRG1 promotes angiogenesis by modulating endothelial TGF-beta signalling. Nature 499, 306-311, doi:10.1038/nature12345 (2013).